A MULTICENTER STUDY WITH ONCE A WEEK OR ONCE EVERY 2 WEEKS HIGH-DOSE SUBCUTANEOUS ADMINISTRATION OF RECOMBINANT-HUMAN-ERYTHROPOIETIN IN CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS
Y. Nomoto et al., A MULTICENTER STUDY WITH ONCE A WEEK OR ONCE EVERY 2 WEEKS HIGH-DOSE SUBCUTANEOUS ADMINISTRATION OF RECOMBINANT-HUMAN-ERYTHROPOIETIN IN CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS, Peritoneal dialysis international, 14(1), 1994, pp. 56-60
Objective: To investigate the effectiveness of administering relativel
y high doses of r-HuEPO subcutaneously once a week or once every 2 wee
ks in patients undergoing continuous ambulatory peritoneal dialysis (C
APD). Design: Multicenter prospective analysis. The trial was divided
into two phases: an initial 8-week phase (once a week dosing) followed
by a 12-week maintenance phase (once every 2 weeks dosing). A respons
e was defined as a change in hematocrit (Ht) of 3% or more. Results we
re analyzed using Sheffe's test, Mantel-Haenszel's test, and Dunnett's
test. Setting: Eleven renal units in Japan providing a CAPD program.
Patients: Forty-one CAPD patients with a Ht of 28% or less. Results: A
fter the initial 8 weeks, 13 (81.3%) of 16 patients showed a response
to 6000 U (106.9+/-20.0 U/kg) subcutaneously (sc), once a week. Eleven
(84.6%) of 13 in the 9000 U (166.5+/-27.7 U/kg) group and all 12 (100
%) in the 12000 U (210.7+/-42.1 U/kg) group also showed responses. At
the end of both phases, that is, at 20 weeks, 7 (53.8%) of 13 patients
in the 6000 U group with once every 2 weeks dosing, 7 (63.6%) of 11 i
n the 9000 U group, and 10 (90.9%) of 11 in the 12000 U group maintain
ed responses with the same dosing interval. There were no significant
changes in mean blood pressure during the study period, and only 2 pat
ients developed treatable hypertension with mild headache. Conclusion:
Administration of relatively high doses of r-HuEPO to CAPD patients o
nce a week or once every 2 weeks is safe and potentially an effective
regimen for the correction of renal anemia.